QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price & News

$21.47
+0.63 (+3.02%)
(As of 10/2/2023 ET)
Compare
Today's Range
$20.31
$21.52
50-Day Range
$20.84
$30.32
52-Week Range
$13.73
$33.99
Volume
2.40 million shs
Average Volume
1.59 million shs
Market Capitalization
$3.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.81

ACADIA Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
48.2% Upside
$31.81 Price Target
Short Interest
Bearish
6.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$3.76 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.41) to $0.60 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

273rd out of 969 stocks

Pharmaceutical Preparations Industry

108th out of 452 stocks


ACAD stock logo

About ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

ACAD Price History

ACAD Stock News Headlines

ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Down 2.5%
Is NVIDIA Leading a "Magnificent Seven Bubble"?
The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks. 
ACAD - ACADIA Pharmaceuticals Inc.
Is NVIDIA Leading a "Magnificent Seven Bubble"?
The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks. 
Dry Eye Syndrome Global Market Report 2023
H.C. Wainwright upgrades Fulcrum Therapeutics (FULC) to a Buy
Here's Why Acadia (ACAD) Looks Ripe for Bottom Fishing
Syros Pharmaceuticals (SYRS) Gets a Buy from JMP Securities
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Company Calendar

Last Earnings
8/02/2023
Today
10/02/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACAD
Employees
540
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.81
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+49.8%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$-215,980,000.00
Pretax Margin
-19.22%

Debt

Sales & Book Value

Annual Sales
$517.23 million
Book Value
$2.47 per share

Miscellaneous

Free Float
118,704,000
Market Cap
$3.48 billion
Optionable
Optionable
Beta
0.65
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Stephen R. Davis J.D. (Age 62)
    Pres, CEO & Director
    Comp: $1.46M
  • Mr. Mark C. Schneyer (Age 49)
    Exec. VP & CFO
    Comp: $701.03k
  • Mr. Brendan P. TeehanMr. Brendan P. Teehan (Age 54)
    Exec. VP, COO & Head of Commercial
    Comp: $724.31k
  • Mr. Austin D. KimMr. Austin D. Kim (Age 59)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $722.15k
  • Mr. James K. KiharaMr. James K. Kihara (Age 42)
    VP, Chief Accounting Officer & Corp. Controller
  • Mr. Bob Mischler
    Sr. VP of Strategy & Technology Operations
  • Mr. Mark C. Johnson
    VP of Investor Relations
  • Ms. Julie Fisher
    Sr. VP of Marketing & Commercial Strategy
  • Ms. Holly Valdiviez
    Sr. VP & Head of Sales
  • Mr. Rob Ackles
    Sr. VP & Chief People Officer













ACAD Stock - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price forecast for 2023?

13 Wall Street analysts have issued 1 year target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price forecasts range from $12.00 to $95.00. On average, they expect the company's share price to reach $31.81 in the next year. This suggests a possible upside of 49.8% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2023?

ACADIA Pharmaceuticals' stock was trading at $15.92 on January 1st, 2023. Since then, ACAD stock has increased by 33.4% and is now trading at $21.24.
View the best growth stocks for 2023 here
.

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 10,700,000 shares, an increase of 5.1% from the August 31st total of 10,180,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the days-to-cover ratio is presently 6.6 days.
View ACADIA Pharmaceuticals' Short Interest
.

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ACAD earnings forecast
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.13. The biopharmaceutical company earned $165.20 million during the quarter, compared to analyst estimates of $163.86 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 27.77% and a negative net margin of 20.11%. The business's revenue for the quarter was up 22.7% compared to the same quarter last year. During the same period last year, the company earned ($0.21) earnings per share.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $21.24.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $3.48 billion and generates $517.23 million in revenue each year. The biopharmaceutical company earns $-215,980,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

The company employs 540 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.

This page (NASDAQ:ACAD) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -